About 30 results found for searched term "Monoamine Oxidase" (0.138 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M2006 | Safinamide Mesylate | Monoamine Oxidase |
| FCE28073, PNU-151774E, NW-1015 | ||
| Safinamide is a highly selective and reversible monoamine oxidase type B (MAO-B) inhibitor. | ||
| M2532 | Clorgyline hydrochloride | Monoamine Oxidase |
| Clorgiline is an irreversible and selective inhibitor of monoamine oxidase A (MAO-A). | ||
| M2880 | Nialamide | Monoamine Oxidase |
| Nialamide is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class used as an antidepressant and anxiolytic. | ||
| M3082 | (1S,2R)-Tranylcypromine hydrochloride | Monoamine Oxidase |
| (1S,2R)-Tranylcypromine hydrochloride is a monoamine oxidase inhibitor, which inhibits CYP2A6 with Ki of 0.08 μM and 0.2 μM in cDNA-expressing microsomes and Human Liver Microsomes, respectively. | ||
| M5710 | Iproniazid phosphate | Monoamine Oxidase |
| Iproniazid is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class. | ||
| M5860 | Pargyline HCl | Monoamine Oxidase |
| Pargyline hydrochloride is an irreversible inhibitor of monoamine oxidase (MAO) that is used clinically to treat moderate hypertension. | ||
| M6026 | Tranylcypromine (2-PCPA) HCl | Monoamine Oxidase |
| SKF-385 HCl; Trans 2-Phenylcyclopropylamine Hydrochloride | ||
| Tranylcypromine HCl is a monoamine oxidase inhibitor, which inhibits CYP2A6 with Ki of 0.08 μM and 0.2 μM in cDNA-expressing microsomes and Human Liver Microsomes, respectively. Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. | ||
| M8233 | M30 dihydrochloride | Others |
| M30 is a site-activated iron chelator and monoamine oxidase (MAO) inhibitor; with neuroprotective and anti-apoptotic activity. | ||
| M8791 | TB5 | Others |
| TB5 is a potent and selective reversible inhibitor of monoamine oxidase B (MAOB) with a Ki value of 110 nM. | ||
| M8804 | Toloxatone | Monoamine Oxidase |
| MD 69276 | ||
| Toloxadone is a reversible monoamine oxidase A inhibitor (MAOI) and antidepressant compound. | ||
| M9090 | Tranylcypromine hemisulfate | Monoamine Oxidase |
| Tranylcypromine sulfate; Tranylcypromine | ||
| Tranylcypromine hemisulfate is a nonselective and irreversible inhibitor of the enzyme monoamine oxidase (MAO). | ||
| M9485 | Eprobemide | Monoamine Oxidase |
| LIS 630 | ||
| Eprobemide is a non-competitive reversible inhibitor of monoamine oxidase A that exhibits selective action on serotonin deamination. | ||
| M14563 | 4-Hydroxyderricin | Monoamine Oxidase |
| 4-Hydroxyderricin, the major active ingredients of Angelica keiskei Koidzumi, is a potent selective MAO-B (Monoamine oxidase inhibitors) inhibitor with an IC50 of 3.43 μM. | ||
| M14564 | Iproniazid | Monoamine Oxidase |
| Iproniazid is a non-selective, irreversible monoamine oxidase (MAO) inhibitor of the hydrazine class. Iproniazid has antidepressive activity. | ||
| M14565 | Isocarboxazid | Monoamine Oxidase |
| Isocarboxazid is a non-selective and irreversible inhibitor of monoamine oxidase, with an IC50 of 4.8 μM for rat brain monoamine oxidase in vitro. | ||
| M14567 | Pargyline | Monoamine Oxidase |
| Pargyline is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline has antihypertensive and anticancer activities. | ||
| M14568 | Rasagiline | Monoamine Oxidase |
| (R)-AGN1135; TVP1012 | ||
| Rasagiline (R-AGN1135) is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC50s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively. | ||
| M14640 | 1,4-Naphthoquinone | Others |
| 1,4-Naphthoquinone is a potential pharmacophore for inhibition of both MAO (monoamine oxidase) and DNA topoisomerase activities, this latter associated with antitumor activity. | ||
| M19368 | Osthenol | Monoamine Oxidase |
| Osthenol (Ostenol) is a selective, reversible, and competitive human monoamine oxidase-A (hMAO-A) inhibitor (Ki=0.26 µM). Osthenol potently inhibits recombinant hMAO-A with an IC50 of 0.74 µM and shows a high selectivity index for hMAO-A versus hMAO-B. | ||
| M20218 | WAY-620147 | Others |
| WAY-620147 is a monoamine oxidase a inhibitor | ||
| M20475 | Safinamide | Others |
| EMD-1195686, PNU-15774E | ||
| Safinamide is an orally active, selective, reversible |
||
| M20569 | Lazabemide | Others |
| Ro 19-6327 | ||
| Lazabemide is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) with Ki value of 7.9 nM. | ||
| M25434 | Tranylcypromine (2-PCPA) HCl (≥97.0%) | Monoamine Oxidase |
| SKF-385 HCl; Trans 2-Phenylcyclopropylamine Hydrochloride | ||
| Tranylcypromine HCl is a monoamine oxidase inhibitor, which inhibits CYP2A6 with Ki of 0.08 μM and 0.2 μM in cDNA-expressing microsomes and Human Liver Microsomes, respectively. Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. | ||
| M27684 | Lazabemide hydrochloride | Monoamine Oxidase |
| Ro 19-6327 hydrochloride | ||
| Lazabemide hydrochloride (Ro 19-6327 hydrochloride) is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) (IC50=0.03 μM) but less active for MAO-A (IC50>100 μM). Lazabemide inhibits monoamine uptake at high concentrations, the IC50 values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and alzheimer′s disease. | ||
| M27802 | Contezolid | Antibiotic |
| MRX-I | ||
| Contezolid (MRX-I), a new and orally active oxazolidinone, is an antibiotic in study for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria. Contezolid (MRX-I) markedly reduces potential for myelosuppression and monoamine oxidase inhibition (MAOI). | ||
| M28789 | hMAO-B-IN-4 | Monoamine Oxidase |
| hMAO-B-IN-4 (compound B10) is a selective, reversible and blood–brain barrier (BBB) penetrable human monoamine oxidase-B (hMAO-B) inhibitor with an IC50 value and a Ki value of 0.067 and 0.03 μM, respectively. hMAO-B-IN-4 inhibits hMAO-A with an IC50 value of 33.82 μM. hMAO-B-IN-4 can be used for Alzheimer’s disease (AD) and Parkinson’s disease (PD) research. | ||
| M28895 | Contezolid acefosamil sodium | Antibiotic |
| MRX-4 sodium | ||
| Contezolid acefosamil sodium (MRX-4), a new and orally active oxazolidinone, is an antibiotic in study for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria. Contezolid acefosamil sodium (MRX-4) markedly reduces potential for myelosuppression and monoamine oxidase inhibition (MAOI). | ||
| M29201 | Ladostigil hydrochloride | Monoamine Oxidase |
| TV-3326 hydrochloride | ||
| Ladostigil (TV-3326) hydrochloride is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC50s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hydrochloride exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease. | ||
| M29202 | Ladostigil | Monoamine Oxidase |
| TV-3326 | ||
| Ladostigil (TV-3326) is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC50s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease. | ||
| M29203 | Ladostigil hemitartrate | Monoamine Oxidase |
| TV-3326 hemitartrate | ||
| Ladostigil (TV-3326) hemitartrate is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC50s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hemitartrate exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil hemitartrate can be used for the research of depression and Alzheimer's disease. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
